1 jan 2004 ano - FDA approves first "anti-angiogenic" drug, bevacizumab
Descrição:
Bavacizumab is the first of a new generation of targeted drugs that attacked cancer by blocking blood flow to the tumors.
Adicionado na linha do tempo:
Cancer Dates
Data:
